Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Alcoholism is one of the most prevalent substance dependence disorders in the world. Advances in research in the neurobiological mechanisms underlying alcohol dependence have identified specific neurotransmitter targets for the development of pharmacological treatments. Acamprosate, marketed under the brand name Campral, is an orally administered drug available by prescription in the U.S. and throughout much of the world for treating alcohol dependence. Its safety and efficacy have been demonstrated in numerous clinical trials worldwide. Here we provide an overview of acamprosate in the context of the neurobiological underpinnings of alcohol dependence. We propose that unlike previously available pharmacotherapies, acamprosate represents a prototypical neuromodulatory approach in the treatment of alcohol dependence. A neuromodulatory approach seeks to restore the disrupted changes in neurobiology resulting from chronic alcohol intake. We believe that a neuromodulatory approach will provide a heuristic framework for developing more effective pharmacotherapies for alcohol dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
The neurobiology of addiction: a neuroadaptational view relevant for diagnosis
Koob, G. F. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01586.x · Cited by 397 · cited 1×
“Insight into the neurocircuitry changes in the human brain associated with the development and maintenance of addiction have come from neuroimaging techniques (eg, positron emission tomography [PET], functional magnetic resonance imaging [fMRI], and magnetic resonance spectroscopy [MRS]) [86].”
MethodNeuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201 · cited 3×
“Several key receptors mediate the response to acute and chronic alcohol intake [4,5].”
BackgroundHeyser, C. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00130-9 · Cited by 176
Self-citationMhatre, M. C., Pena, G., Sieghart, W., & Ticku, M. K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09795.x · Cited by 174
Dahchour, A., De Witte, P., Bolo, N., Nédélec, J.-F., Muzet, M., Durbin, P., & Macher, J.-P. (1998) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(98)00016-x · Cited by 165 · cited 2×
“The results suggest a central glutamatergic effect of acamprosate that is consistent with glutamate measurements in alcoholized rats treated with acamprosate [49].”
BackgroundResultDevelopment of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Self-citationSnell, L. D., Tabakoff, B., & Hoffman, P. L. (1993) · Brain Research · doi:10.1016/0006-8993(93)90246-j · Cited by 147
Le Magnen, J., Tran, G., Durlach, J., & Martin, C. (1987) · Alcohol · doi:10.1016/0741-8329(87)90005-x · Cited by 97 · cited 2×
“[63] reported a 50–70% reduction in ethanol intake in ethanol dependent animals after the administration of 200 mg/ kg acamprosate, where only a dose of 450 mg/kg reduced drinking in alcohol-naïve animals.”
BackgroundIncreased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study
Davidson, M., Shanley, B., & Wilce, P. (1995) · Brain Research · doi:10.1016/0006-8993(94)01440-s · Cited by 94
Cited by
Addiction and Brain Reward and Antireward Pathways
Gardner, E. L. (2011) · Advances in Psychosomatic Medicine · doi:10.1159/000324065 · Cited by 417
Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework
Koob, G. F., & Colrain, I. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0446-0 · Cited by 276
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“While the specific mechanisms through which acamprosate works to treat AUD remain under investigation, it is thought to act on the glutamatergic system as an N-methyl-d-aspartic acid (NMDA) receptor partial co-agonist [35].”
BackgroundGabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
“mediated glutamergic neurotransmission [19,21], and the calcium mechanism is controversial [22].”
Self-citationAcamprosate: a review of its use in alcohol dependence
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0423-9 · Cited by 65
“Acamprosate has also been investigated as augmentation therapy in the management of anxiety because of its pharmacodynamic effects of restoring pathological imbalances between neuronal excitation by glutamate and neuronal inhibition by GABA [58, 59].”
BackgroundInfluential
Metadata
- Authors
- Mason, B., & Heyser, C.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-03-01
- Volume
- 9
- Issue
- 1
- Pages
- 23-32
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2051915373
- Cited by
- 103
- References
- 11
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence. https://app.cochat.ai/papers/10.2174/187152710790966641
- The paper
- Mason, B., & Heyser, C. (2010). Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152710790966641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.